The effects of gender difference on monocrotaline-induced pulmonary hypertension in rats

Human and Experimental Toxicology

Volumn 32, Issue 7, 2013, Pages 766-774

  Bal, E ^a   Ilgin, S ^a   Atli, O ^a   Ergun, B ^a   Sirmagul, B ^b  

^a ANADOLU UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

gender; monocrotaline; oxidative stress; Pulmonary hypertension

Indexed keywords

CATALASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MONOCROTALINE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HEART WEIGHT; HEMODYNAMIC PARAMETERS; LIVER; LUNG ARTERY PRESSURE; LUNG PARENCHYMA; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SEX DIFFERENCE;

GENDER; MONOCROTALINE; OXIDATIVE STRESS; PULMONARY HYPERTENSION;

ANIMALS; CATALASE; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LIVER; LUNG; MALE; MONOCROTALINE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; SUPEROXIDE DISMUTASE; VENTRICULAR PRESSURE;

RATTUS;

EID: 84879762702     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327113477874     Document Type: Article

References (48)

1. Ahn BH, Park HK, Cho HG, et al. Estrogen and enalapril attenuate the development of right ventricular hypertrophy induced by monocrotaline in ovariectomized rats. J Korean Med Sci. 2003 ; 18 (5). 641-8
2. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996 ; 10: 615-624
3. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res. 2002 ; 53 (3). 597-604
4. Patel KM, Lahm T, Crisostomo PR, et al. The effects of endogenous sex hormones and acute hypoxia on vasoconstriction in isolated rat pulmonary artery ring. J Surg Res. 2008 ; 146 (1). 121-126
5. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest. 2003 ; 112 (3). 302-307
6. Orshal JM, Khalil RA. Gender, sex hormones and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004 ; 286 (2). 233-249
7. Dubey RK, Imthurn B, Barton M, et al. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovas Res. 2005 ; 66 (2). 295-306
8. Patel PD, Arora RR.. Endothelial dysfunction: a potential tool in gender related cardiovascular disease. Ther Adv Cardiovasc Dis. 2008 ; 2 (2). 89-100
9. Bittner V. Menopause, age and cardiovascular risk. J Am Coll Cardiol. 2009 ; 54 (25). 2374-2375
10. Schwertz DW, Penckofer S. Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung. 2001 ; 30 (6). 401-426
11. Warnes CA. Sex differences in congenital heart disease: should a woman be more like a man?. Circulation. 2008 ; 118 (1). 3-5
12. Carey MA, Card CW, Voltz JM, et al. It's all about sex: male-female differences in lung development and disease. Trends Endocrinol Metab. 2007 ; 18 (8). 308-313
13. Sakao S, Tanabe N, Tatsumi K. The estrogen paradox in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2010 ; 299 (4). 435 438
14. Tofovic SP, Zhang X, Zhu H, et al. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol. 2008 ; 48 ((4-6)). 174-183
15. Lahm T, Albrecht M, Fisher AJ, et al. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med. 2012 ; 185 (9). 965-980
16. Tofovic S. Estrogens and development of pulmonary hypertension - interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol. 2010 ; 56 (6). 696-708
17. Miller AA, Silva TM, Jackman KA, et al. Effects of gender and sex hormones on vascular oxidative stress. Clin Exp Pharmacol Physiol. 2007 ; 34 (10). 1037-1043
18. Malorni W, Straface E, Matarrese P, et al. Redox state and gender differences in vascular smooth muscle cells. FEBS Lett. 2008 ; 582 (5). 635-642
19. Wang J, Liang Q, Ji L, et al. Gender-related difference in liver injury induced by Dioscorea bulbifera L. Rhizome in mice. Hum Exp Toxicol. 2011 ; 30 (9). 1333-1341
20. Lopez-Ruiz A, Sartori-Valinotti J, Yanes LL, et al. Sex differences in control of blood pressure: role of oxidative stress in hypertension in females. Am J Physiol Heart Circ Physiol. 2008 ; 295 (2). 466-474
21. Sartori-Valinotti JC, Iliescu R, Fortepiani LA, et al. Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease. Clin Exp Pharmacol Physiol. 2007 ; 34 (9). 938-945
22. Coto-Montes A, Boga JA, Tomas-Zapico C, et al. Physiological oxidative stress model: Syrian hamster Harderian gland-sex differences in antioxidant enzymes. Free Radic Biol Med. 2001 ; 30 (7). 785-792
23. Li XQ, Hong Y, Wang Y, et al. Sertraline protects against monocrotaline induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol. 2006 ; 33 (11). 1047-1051
24. Schultze AE, Roth RA. Chronic pulmonary hypertension-the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B: Crit Rev. 1998 ; 1 (4). 271-346
25. Copple BL, Ganey PE, Roth RA. Liver inflammation during monocrotaline hepatotoxicity. Toxicology. 2003 ; 190 (3). 155-169
26. Campian ME, Hardziyenka M, Michel MC, et al. How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn Schmiedebergs Arch Pharmacol. 2006 ; 373 (6). 391-400
27. Pichardo J, Palace V, Farahmand F, et al. Myocardial oxidative stress changes during compensated right heart failure in rats. Mol Cell Biochem. 1999 ; 196 ((1-2)). 51-57
28. Kamezaki F, Tasaki H, Yamashita K, et al. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med. 2008 ; 177 (2). 219-226
29. Amin KA, Hassan MS, Awad ES, et al. The protective effects of cerium oxide nanoparticles against hepatic oxidative damage induced by monocrotaline. Int J Nanomed. 2011 ; 6: 143-149
30. Deleve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996 ; 23 (3). 589-599
31. Kang KK, Ahn GJ, Ahn B, et al. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J Int Med Res. 2003 ; 31 (6). 517-528
32. Nagaoka T, Fagan KA, Gebb SA, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med. 2005 ; 171 (5). 494-499
33. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ. 1995 ; 311 (7014). 1193-1196
34. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003 ; 24 (3). 313-340
35. Kodama K, Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline induced pulmonary hypertensive rats. J Pharmacol Exp Ther. 1999 ; 290 (2). 748-752
36. Toher CA. Update on pulmonary hypertension diagnosis, pathophysiology and treatment. The Bulletin. 2005 ; 47: 45-54
37. Levine DJ. Diagnosis and management of pulmonary arterial hypertension: implications for respiratory care. Respir Care. 2006 ; 51 (4). 368-381
38. Tofovic SP, Salah EM, Mady HH, et al. Estradiol metabolites attenuate monocrotaline-induce pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2005 ; 46 (4). 430-437
39. Tofovic SP, Zhang X, Jackson EK, et al. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol. 2006 ; 45 (6). 358-367
40. Siqueira R, Campos R, Colombo R, et al. Influence of estrogen on pulmonary arterial hypertension: role of oxidative stress. Cell Biochem Funct. 2011 ; 29: 543-548
41. Azevedo RB, Lacava ZGM, Chaves SB, et al. Regulation of antioxidant enzyme activities in male and female rat macrophages by sex steroids. Braz J Med Biol Res. 2001 ; 34 (5). 683-687
42. Hackenhaar FS, Salomon TB, Alabarse PVG, et al. Pulmonary antioxidant defenses and protein damage during the ageing process of both sexes. Cell Biochem Funct. 2009 ; 27 (6). 378-382
43. Jin H, Du S, Zhao X, et al. Effects of endogenous sulfur dioxide on monocrotaline-induced pulmonary hypertension in rats. Acta Pharmacol Sin. 2008 ; 29 (10). 1157-1166
44. Ludke AR, Mosele F, Caron-Lienert R, et al. Modulation of monocrotaline-induced cor pulmonale by grape juice. J Cardiovasc Pharmacol. 2010 ; 55 (1). 89-95
45. Farahmand F, Hill MF, Singal PK. Antioxidant and oxidative stress changes in experimental cor pulmonale. Mol Cell Biochem. 2004 ; 260 ((1-2)). 21-29
46. Yamamoto T, Ohkuwa T, Itoh H, et al. Effect of gender differences and voluntary exercise on antioxidant capacity in rats. Comp Biochem Physiol C: Toxicol Pharmacol. 2002 ; 132 (4). 437-44
47. Depboylu B, Giris M, Olgac V, et al. Response of liver to lipopolysaccharide treatment in male and female rats. Exp Toxicol Pathol.:
48. Pérez-Torres I, Roque P, El Hafidi M, et al. Association of renal damage and oxidative stress in a rat model of metabolic syndrome: influence of gender. Free Radic Res. 2009 ; 43 (8). 761-771